IDIA — Idorsia Share Price
Last trade - 00:00- CH₣255.63m
- CH₣1.29bn
- CH₣112.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -370.06% | ||
| Return on Equity | n/a | ||
| Operating Margin | -206.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 71.76 | 35.35 | 97.1 | 152.39 | 112.51 | 160.07 | 292.85 | 36.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Directors
- Mathieu Simon NEC (65)
- Jean-Paul Clozel CEO (66)
- Andre Muller CFO (58)
- Martine Clozel EVP (66)
- Simon Jose EVP (56)
- Guy Braunstein EVP (65)
- Alberto Gimona EVP (61)
- Joern Aldag NID (62)
- Felix Ehrat NID (64)
- Srishti Gupta NID (45)
- Peter Kellogg NID (65)
- Sandy Mahatme NID (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 3rd, 2017
- Public Since
- June 16th, 2017
- No. of Employees
- 938
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 224,238,663
- Address
- Hegenheimermattweg 91, ALLSCHWIL, 4123
- Web
- https://www.idorsia.com
- Phone
- Auditors
- Deloitte AG
Latest News for IDIA
Upcoming Events for IDIA
Q1 2025 Idorsia Ltd Earnings Release
Idorsia Ltd Annual Shareholders Meeting
Idorsia Ltd Annual Shareholders Meeting
Half Year 2025 Idorsia Ltd Earnings Release
Similar to IDIA
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
As of Today at 21:13 UTC, shares in Idorsia are trading at CH₣1.14. This share price information is delayed by 15 minutes.
Shares in Idorsia last closed at CH₣1.14 and the price had moved by -37.36% over the past 365 days. In terms of relative price strength the Idorsia share price has underperformed the FTSE Global All Cap Index by -38.47% over the past year.
The overall consensus recommendation for Idorsia is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIdorsia does not currently pay a dividend.
Idorsia does not currently pay a dividend.
Idorsia does not currently pay a dividend.
To buy shares in Idorsia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣1.14, shares in Idorsia had a market capitalisation of CH₣255.63m.
Here are the trading details for Idorsia:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: IDIA
Based on an overall assessment of its quality, value and momentum Idorsia is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Idorsia is CH₣1.60. That is 40.35% above the last closing price of CH₣1.14.
Analysts covering Idorsia currently have a consensus Earnings Per Share (EPS) forecast of -CH₣0.80 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Idorsia. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -0.31%.
As of the last closing price of CH₣1.14, shares in Idorsia were trading -14.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Idorsia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣1.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Idorsia's management team is headed by:
- Mathieu Simon - NEC
- Jean-Paul Clozel - CEO
- Andre Muller - CFO
- Martine Clozel - EVP
- Simon Jose - EVP
- Guy Braunstein - EVP
- Alberto Gimona - EVP
- Joern Aldag - NID
- Felix Ehrat - NID
- Srishti Gupta - NID
- Peter Kellogg - NID
- Sandy Mahatme - NID